List of contributors | p. ix |
Foreword | p. xi |
Preface | p. xiii |
Acknowledgments | p. xvi |
Basic science | p. 1 |
Basic science | p. 3 |
Hematologic malignancies | p. 21 |
Therapeutic decision making in BMT/SCT for acute myeloid leukemia | p. 23 |
Therapeutic decision making in BMT/SCT for acute lymphoblastic leukemia | p. 41 |
Therapeutic decision making in BMT/SCT for chronic myeloid leukemia and other myeloproliferative syndromes | p. 57 |
Therapeutic decision making in BMT/SCT for chronic lymphatic leukemia | p. 71 |
Therapeutic decision making in BMT/SCT for myelodysplasia | p. 85 |
Therapeutic decision making in BMT/SCT for non-Hodgkin Lymphoma | p. 99 |
Therapeutic decision making in BMT/SCT for Hodgkin lymphoma | p. 127 |
Therapeutic decision making in hematopoietic stem cell transplantation for multiple myeloma | p. 139 |
Therapeutic decision making in BMT/SCT for amyloidosis | p. 157 |
Solid tumors | p. 163 |
Therapeutic decision making in stem cell transplantation for breast cancer | p. 165 |
Therapeutic decision making in BMT/SCT for nonseminomatous germ cell tumor of testis (NSGCT) | p. 169 |
Therapeutic decision making in BMT/SCT for renal cell cancer | p. 177 |
Therapeutic decision making in BMT/SCT for soft tissue sarcomas | p. 189 |
Nonmalignant disorders | p. 195 |
Therapeutic decision making in BMT/SCT for severe aplastic anemia | p. 197 |
Therapeutic decision making in BMT/SCT for congenital immunodeficiencies | p. 205 |
Therapeutic decision making in BMT/SCT for hemoglobinopathies | p. 215 |
Therapeutic decision making in BMT/SCT for autoimmune disorders | p. 227 |
Practical aspects and procedures | p. 233 |
Practical aspects and procedures, including conditioning protocols and haploidentical transplantation | p. 235 |
Umbilical cord blood as alternative allogeneic graft source: clinical banking and transplant outcomes | p. 301 |
Complications | p. 311 |
Pathobiology of graft-versus-host disease | p. 313 |
Diagnosis and treatment of graft-versus-host-disease | p. 331 |
Management and prophylaxis of infections after BMT/SCT | p. 357 |
Organ-related and miscellaneous complications | p. 379 |
The BMT/SCT pharmacopoeia | p. 429 |
The BMT/SCT pharmacopoeia | p. 431 |
HLA-testing and laboratory medicine | p. 493 |
HLA-testing and laboratory medicine | p. 495 |
Appendix | p. 511 |
Index | p. 515 |
Table of Contents provided by Ingram. All Rights Reserved. |
The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.
The Used, Rental and eBook copies of this book are not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.